Table 2.

Univariate analyses of community-acquired and nosocomial CDI

	Community-onset n=55 (84.6%)	Nosocomial n=10 (15.4%)	P	OR (95% CI)
Sex, n (%)
Female	27 (49.1)	6 (60)	0.73	1.5 (0.4-6.13)
Male	28 (50.9)	4 (40)
Age groups, n (%)
18-28	15 (27.3)	1 (10)	0.003*
29-38	16 (29.1)	0
39-48	15 (27.3)	1 (10)
49-58	3 (5.5)	3 (30)
59-65	3 (5.5)	2 (31)
>65	3 (5.5)	3 (30)
Presence of IBD, n (%)	41 (74.5)	3 (30)	0.01*	6.8 (1.5-30.08)
Previous antibiotic use,** n (%)	25 (45.5)	9 (90)	0.01*	0.09 (0.01-0.78)
Previous PPI use, n (%)	22 (40)	4 (40)	1	1 (0.25-3.95)
Immunosuppressive therapy, n (%)	29 (52.7)	4 (40)	0.5	1.6 (0.42-6.64)
Malignancy, n (%)	2 (3.6)	2 (31)	0.1	0.15 (0.01-1.22)

OR: Odds ratio; CI: Confidence interval; IBD: Inflammatory bowel disease; PPI: Proton pump inhibitor, *P≤0.05 was considered statistically significant, **Patients who used antibiotics in last 3 months